[1] S. B. Olasupo, A. Uzairu, G. S. Adamu, and S. Uba, “Computational Modeling and Pharmacokinetics/ADMET Study of Some Arylpiperazine Derivatives as Novel Antipsychotic Agents Targeting Depression,” Chem. Africa., 3 (2020) 1–10.
[2] N. Dessalew, “QSAR study on dual SET and NET reuptake inhibitors: an insight into the structural requirement for antidepressant activity,” J. Enzyme Inhib. Med. Chem.., 24 (2009) 262–271.
[3] S. B. Olasupo, A. Uzairu, G. A. Shallangwa, and S. Uba, “Profiling the antidepressant properties of Phenyl piperidine derivatives as inhibitors of serotonin transporter (SERT) via Cheminformatics Modeling, Molecular docking and ADMET predictions.,” Sci. African., 9 (2020) p. e00517.
[4] M. Gabrielsen, A. W. Ravna, K. Kristiansen, and I. Sylte, “Substrate binding and translocation of the serotonin transporter studied by docking and molecular dynamics simulations,” J. Mol. Model., 18 (2012) 1073–1085.
[5] I. C. Muszynski, L. Scapozza, K. Kovar, and G. Folkers, “Quantitative structure‐activity relationships of phenyltropanes as inhibitors of three monoamine transporters: Classical and CoMFA studies,” Quant. Struct. Relationships., 18 (1999) 342–353.
[6] S. Bhat, A. H. Newman, and M. Freissmuth, “How to rescue misfolded SERT, DAT and NET: targeting conformational intermediates with atypical inhibitors and partial releasers,” Biochem. Soc. Trans., 47 (2019) 861–874.
[7] Y. Yang et al., “Computational analysis of structure-based interactions for novel H1-antihistamines,” Int. J. Mol. Sci., 17 (2016) 129.
[8] J. Wang et al., “Profiling the interaction mechanism of indole-based derivatives targeting the HIV-1 gp120 receptor,” RSC Adv., 5 (2015) 78278–78298.
[9] S. B. Olasupo, A. Uzairu, G. Shallangwa, and S. Uba, “QSAR analysis and molecular docking simulation of norepinephrine transporter (NET) inhibitors as anti-psychotic therapeutic agents,” Heliyon., 5 (2019) e02640.
[10] A. Penmatsa, K. H. Wang, and E. Gouaux, “X-ray structure of dopamine transporter elucidates antidepressant mechanism,” Nature., 503 (2013) 85.
[11] P. T. Mpiana et al., “Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: a molecular docking study,” Chem. Phys. Lett., 754 (2020) 137751
[12] S. S. ul Hassan, W.-D. Zhang, H. Jin, S. H. Basha, and S. V. S. S. Priya, “In-silico anti-inflammatory potential of guaiane dimers from Xylopia vielana targeting COX-2,” J. Biomol. Struct. Dyn., 1 (2020) 1–15.
[13] A. Daina, O. Michielin, and V. Zoete, “SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules,” Sci. Rep., 7 (2017) 42717.
[14] D. E. V Pires, T. L. Blundell, and D. B. Ascher, “pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures,” J. Med. Chem., 58 (2015) 4066–4072.
[15] M. Cheminformatics, “Calculation of molecular properties and bioactivity score,” Comput. software]. Retrieved from http//www. molinspiration. com/cgi-bin/properties, (2018).
[16] F. Cheng et al., “Correction to ‘admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties,’” J. Chem. Inf. Model., 59 (2019) 4959.
[17] C. A. Lipinski, “Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions,” Adv. Drug Deliv. Rev., 101 (2016) 34–41.
[18] S. B. Olasupo, A. Uzairu, G. A. Shallangwa, and S. Uba, “Chemoinformatic studies on some inhibitors of dopamine transporter and the receptor targeting schizophrenia for developing novel antipsychotic agents,” Heliyon, 6 (2020) e04464.
[19] N. Brooijmans, “Docking methods, ligand design, and validating data sets in the structural genomic era,” Struct. Bioinformatics. JGaPE Bourne, Ed. John Wiley Sons, ( 2009)
[20] S. Roy, L. R. Samant, and A. Chowdhary, “In silico pharmacokinetics analysis and ADMET of phytochemicals of Datura metel Linn. and Cynodon dactylon Linn,” J. Chem. Pharm. Res., 7 (2015) 385–388.
[21] A. Daina and V. Zoete, “A boiled‐egg to predict gastrointestinal absorption and brain penetration of small molecules,” ChemMedChem., 11 (2016) 1117–1121.
[22] S. Babatunde, O. Adamu, U. Gideon, and S. Sani, “QSAR modeling , molecular docking and ADMET / pharmacokinetic studies : a chemometrics approach to search for novel inhibitors of norepinephrine transporter as potent antipsychotic drugs,” J. Iran. Chem. Soc., 17 (2020) 1953–1966.
[23] S. E. Adeniji, D. E. Arthur, M. Abdullahi, and A. Haruna, “Quantitative structure–activity relationship model, molecular docking simulation and computational design of some novel compounds against DNA gyrase receptor,” Chem. Africa, 3 (2020) 391–408.